Specific immune response in atezolizumab and bevacizumab

Specific immune response in atezolizumab and bevacizumab - Specific immune response in atezolizumab and bevacizumab

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047777

Enrollment

100

Registered

2022-05-17

Start date

2022-02-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab 2) with informed consent

Exclusion criteria

Exclusion criteria: 1) patients refusal 2) inadequate patients

Design outcomes

Primary

Measure	Time frame
enhancement of HCC specific anti-tumor immune responses	—

Secondary

Measure	Time frame
clinicopathological factors, progression-free survival, tumor response, overall survival	—

Countries

Japan

Contacts

Public ContactTakeshi Terashima

Kanazawa University Advanced Preventive Medical Sciences Research Center

tera@m-kanazawa.jp076-265-2235

Outcome results